Alpha DNA Investment Management LLC Buys Shares of 12,218 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Alpha DNA Investment Management LLC purchased a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 12,218 shares of the specialty pharmaceutical company’s stock, valued at approximately $442,000.

Other institutional investors have also modified their holdings of the company. HighTower Advisors LLC purchased a new stake in Supernus Pharmaceuticals in the 3rd quarter worth approximately $264,000. Stifel Financial Corp grew its position in shares of Supernus Pharmaceuticals by 1.6% in the third quarter. Stifel Financial Corp now owns 69,134 shares of the specialty pharmaceutical company’s stock valued at $2,156,000 after purchasing an additional 1,093 shares during the period. Barclays PLC increased its stake in Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after purchasing an additional 51,005 shares during the last quarter. Geode Capital Management LLC lifted its position in Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after buying an additional 74,438 shares during the period. Finally, Franklin Resources Inc. boosted its stake in Supernus Pharmaceuticals by 7.6% in the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock worth $987,000 after buying an additional 2,121 shares during the last quarter.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $30.76 on Friday. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The company has a market cap of $1.72 billion, a price-to-earnings ratio of 28.75 and a beta of 0.90. The stock’s 50-day moving average is $32.76 and its 200-day moving average is $35.01.

Insider Activity at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 700 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,103.38. This represents a 6.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,104 shares of company stock worth $440,263. Company insiders own 9.30% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SUPN. Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.